We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+42.53%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$1.12B
(+60%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
21.57%
Top 10 Holdings %
Top 10 Hldgs %
39.7%
Holding
119
New
52
Increased
25
Reduced
7
Closed
24
Top Buys
| 1 |
AstraZeneca
AZN
|
+$122M |
| 2 |
Eli Lilly
LLY
|
+$121M |
| 3 |
Maravai LifeSciences
MRVI
|
+$96M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$78.7M |
| 5 |
Avantor
AVTR
|
+$51.7M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$104M |
| 2 |
Merck
MRK
|
+$94.9M |
| 3 |
Biogen
BIIB
|
+$81.3M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$67.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$52.2M |
Sector Composition
| 1 | Healthcare | 94.3% |
| 2 | Technology | 1.93% |
| 3 | Financials | 0.19% |
| 4 | Industrials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Avantor
AVTR
$7.65B
| $185M | 6.21% |
6,566,700
+2,004,300
| +44% | +$51.7M |
|
2
Arvinas
ARVN
$534M
| $152M | 5.1% |
1,787,358
+439,058
| +33% | +$15.1M |
|
3
AbbVie
ABBV
$431B
| $145M | 4.88% |
1,356,000
-166,800
| -11% | -$16M |
|
|
4
Eli Lilly
LLY
$1.03T
| $137M | 4.6% |
+810,500
| New | +$121M |
|
|
5
AstraZeneca
AZN
$261B
| $115M | 3.87% |
+1,150,000
| New | +$122M |
|
|
6
Maravai LifeSciences
MRVI
$1.04B
| $96.7M | 3.25% |
+3,445,772
| New | +$96M |
|
7
Quest Diagnostics
DGX
$22.3B
| $94.4M | 3.17% |
792,100
+390,100
| +97% | +$47.6M |
|
|
8
BioMarin Pharmaceuticals
BMRN
$11.4B
| $87.1M | 2.93% |
+992,900
| New | +$78.7M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $85.5M | 2.88% |
1,169,300
+239,100
| +26% | +$17.8M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $83.5M | 2.81% |
380,000
+105,000
| +38% | +$22.7M |
|
|
NBP
11
NovaBridge Biosciences American Depositary Shares
NBP
$214M
| $75M | 2.52% |
1,591,000
+251,000
| +19% | +$9.88M |
|
12
Syndax Pharmaceuticals
SNDX
$2.08B
| $73.6M | 2.47% |
3,308,000
+1,453,900
| +78% | +$30.2M |
|
|
13
CALL
Biogen
BIIB
$29.1B
| $60.7M | 2.04% |
248,100
+34,000
| +16% | +$8.77M |
|
14
Zentalis Pharmaceuticals
ZNTL
$340M
| $59M | 1.98% |
1,135,000
+230,881
| +26% | +$10.4M |
|
|
CHNG
15
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $57.5M | 1.93% |
3,082,100
+554,600
| +22% | +$9.11M |
|
16
Shattuck Labs
STTK
$647M
| $49.2M | 1.65% |
+938,813
| New | +$30.2M |
|
17
Natera
NTRA
$39.7B
| $47.8M | 1.61% |
479,800
-23,600
| -5% | -$1.97M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $47.7M | 1.6% |
+621,000
| New | +$46.5M |
|
|
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
| $46.9M | 1.58% |
+757,000
| New | +$43.3M |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $46.9M | 1.58% |
3,185,200
+1,439,200
| +82% | +$20.8M |
|
|
BHVN
21
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $44.7M | 1.5% |
+521,100
| New | +$44.2M |
|
|
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
| $44.3M | 1.49% |
774,000
+150,700
| +24% | +$6.37M |
|
23
Cardinal Health
CAH
$52.7B
| $43.3M | 1.45% |
+808,000
| New | +$41.9M |
|
|
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $42.2M | 1.42% |
491,800
-792,400
| -62% | -$67.1M |
|
25
Organogenesis Holdings
ORGO
$320M
| $41.6M | 1.4% |
+5,521,500
| New | +$26.2M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH